Organon

Organon & Co. emerged as a standalone entity in June 2021, following a strategic spin-off from the pharmaceutical giant Merck & Co., known as MSD outside North America. This pivotal moment marked the beginning of a new chapter for Organon, positioning itself as a global leader in women's health, biosimilars, and established brands.

Originally, Organon was a Dutch pharmaceutical company with a rich history dating back to its founding in 1923. It was renowned for its contributions to reproductive medicine and contraception. Over the decades, Organon became a part of Merck & Co. through acquisition, which expanded its reach and capabilities.

The spin-off in 2021 was a significant event, allowing Organon to focus on its core mission of delivering impactful health solutions, particularly in women's health. This move was designed to unlock value for shareholders and provide Organon with the agility to pursue growth opportunities independently.

Since becoming independent, Organon has actively pursued acquisitions to bolster its portfolio, including companies like Dermavant, Forendo Pharma, and Alydia Health. These strategic moves have strengthened Organon's position in the healthcare sector, particularly in women's health and dermatology.

Today, Organon is headquartered in the United States and trades on the New York Stock Exchange under the ticker symbol OGN. The company's journey from a historic Dutch pharmaceutical firm to a modern, independent leader in women's health underscores its commitment to innovation and improving health outcomes globally.